Lifecore Biomedical Stock Annual Yield
LFCR Stock | 6.13 0.11 1.83% |
Lifecore Biomedical fundamentals help investors to digest information that contributes to Lifecore Biomedical's financial success or failures. It also enables traders to predict the movement of Lifecore Stock. The fundamental analysis module provides a way to measure Lifecore Biomedical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Lifecore Biomedical stock.
Lifecore | Annual Yield |
Lifecore Biomedical Company Annual Yield Analysis
Lifecore Biomedical's Yield generally refers to the amount of cash that is paid back to the owner of a security over a specific time (usually one year). It is expressed as a percentage of current market price, and usually amounts to all the interests and/or dividends paid over a given period. A higher yield allows the shareholders to generate returns on their investments sooner. However, investors should also be aware that a high yield may be a result of market turmoil or increased price volatility.
Lifecore Annual Yield Driver Correlations
Understanding the fundamental principles of building solid financial models for Lifecore Biomedical is extremely important. It helps to project a fair market value of Lifecore Stock properly, considering its historical fundamentals such as Annual Yield. Since Lifecore Biomedical's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Lifecore Biomedical's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Lifecore Biomedical's interrelated accounts and indicators.
Click cells to compare fundamentals
Small firms, start-ups, or companies with high growth potential typically do not pay out dividends or distribute a lot of their profits. These companies will have small yield. Alternatively, more established companies, ETFs, and funds that invest in bonds will have higher yields.
Competition |
In accordance with the recently published financial statements, Lifecore Biomedical has an Annual Yield of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Share Portfolio Now
Share PortfolioTrack or share privately all of your investments from the convenience of any device |
All Next | Launch Module |
Lifecore Biomedical ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Lifecore Biomedical's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Lifecore Biomedical's managers, analysts, and investors.Environmental | Governance | Social |
Lifecore Fundamentals
Return On Equity | 0.17 | ||||
Return On Asset | -0.0225 | ||||
Profit Margin | 0.05 % | ||||
Operating Margin | (0.37) % | ||||
Current Valuation | 344.78 M | ||||
Shares Outstanding | 37.03 M | ||||
Shares Owned By Insiders | 5.44 % | ||||
Shares Owned By Institutions | 69.84 % | ||||
Number Of Shares Shorted | 2.59 M | ||||
Price To Book | 14.43 X | ||||
Price To Sales | 1.74 X | ||||
Revenue | 128.26 M | ||||
Gross Profit | 44.51 M | ||||
EBITDA | 35.6 M | ||||
Net Income | 9.33 M | ||||
Total Debt | 130.36 M | ||||
Book Value Per Share | 0.37 X | ||||
Cash Flow From Operations | (217 K) | ||||
Short Ratio | 11.92 X | ||||
Earnings Per Share | (0.56) X | ||||
Price To Earnings To Growth | 3.51 X | ||||
Target Price | 8.5 | ||||
Number Of Employees | 524 | ||||
Beta | 0.94 | ||||
Market Capitalization | 222.89 M | ||||
Total Asset | 273.7 M | ||||
Retained Earnings | (166.52 M) | ||||
Working Capital | 42.16 M | ||||
Net Asset | 273.7 M |
About Lifecore Biomedical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Lifecore Biomedical's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Lifecore Biomedical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Lifecore Biomedical based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Additional Tools for Lifecore Stock Analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.